Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16040183 | 0.87 | HTR3A (0.45) | KDM4EHSD17B10GAAALDH1A1NCF1 | |
| SCHEMBL16039735 | 0.86 | ALDH1A1 (0.48) | KDM4EHSD17B10TDP1L3MBTL1POLB | |
| SCHEMBL17478816 | 0.80 | ALDH1A1 (0.53) | KDM4EHSD17B10GAATDP1L3MBTL1 | |
| SCHEMBL16040403 | 0.79 | CKS1B (0.49) | ALDH1A1GBA1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL17479576 | 0.79 | ALDH1A1 (0.48) | KDM4EHSD17B10GAATDP1L3MBTL1 | |
| SCHEMBL17479670 | 0.76 | KDM4E (0.40) | KDM4EHSD17B10GAATDP1L3MBTL1 | |
| SCHEMBL29912154 | 0.75 | HCRTR2 (0.52) | HCRTR2HCRTR1 | |
| SCHEMBL261755 | 0.75 | HCRTR2 (0.52) | HCRTR2HCRTR1 | |
| SCHEMBL2492982 | 0.75 | KDM4E (0.54) | KDM4EHSD17B10ALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL28825836 | 0.74 | NCF1 (0.45) | KDM4EGAATDP1ALDH1A1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105209468-B | Substitution 7 Azabicyclic compounds and they as orexin receptor conditioning agent purposes | 詹森药业有限公司 | 2017-09-08 | — | — | CN | disclosed |
| US-9695183-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-04 | — | — | US | disclosed |
| US-9637496-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-02 | — | — | US | disclosed |
| US-20160376280-A1 | Substituted 7-Azabicycles And Their Use As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-29 | — | — | US | disclosed |
| US-9475819-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-25 | — | — | US | disclosed |
| US-20160046640-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| CN-105209468-A | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | disclosed |
| US-20150328224-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-19 | — | — | US | disclosed |
| US-9062078-B2 | Substituted 7-azabicyles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20140275065-A1 | SUBSTITUTED 7-AZABICYLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046640-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, HTR7 | KDM4E 933/4885HSD17B10 2910/4885GAA 2057/4885 |
| US-20150328224-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, NPY5R | KDM4E 1382/4885HSD17B10 2083/4885GAA 3167/4885 |
| US-20160376280-A1 | Substituted 7-Azabicycles And Their Use As Orexin Receptor Modulators | HCRTR2, HCRTR1, NPY5R | KDM4E 1287/4885HSD17B10 2131/4885GAA 3307/4885 |
| US-20140275065-A1 | SUBSTITUTED 7-AZABICYLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, NPY5R | KDM4E 1549/4885HSD17B10 2025/4885GAA 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.